(Q35584012)

9 August 2017

title

FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma (English)

1 reference

9 August 2017

author name string

Virginia E Kwitkowski

1

1 reference

9 August 2017

Tatiana M Prowell

2

1 reference

9 August 2017

Amna Ibrahim

3

1 reference

9 August 2017

Ann T Farrell

4

1 reference

9 August 2017

Robert Justice

5

1 reference

9 August 2017

Shan Sun Mitchell

6

1 reference

9 August 2017

Rajeshwari Sridhara

7

1 reference

9 August 2017

Richard Pazdur

8

1 reference

9 August 2017

publication date

23 March 2010

1 reference

9 August 2017

1 reference

9 August 2017

volume

15

1 reference

9 August 2017

issue

4

1 reference

9 August 2017

page(s)

428-435

1 reference

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227966

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227966

Sorafenib for the treatment of advanced renal cell carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227966

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227966

Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227966

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227966

Surgery of renal cell carcinoma.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227966

Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators

26 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20332142

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1634/THEONCOLOGIST.2009-0178

1 reference

9 August 2017

1 reference

9 August 2017

1 reference